This clinical trial is focused on studying the effects of a medication called amantadine on people with advanced Parkinson’s disease. Parkinson’s disease is a condition that affects the brain and leads to symptoms like shaking, stiffness, and difficulty with balance and coordination. As the disease progresses, patients often experience “motor fluctuations,” which means their ability to move can vary throughout the day. The study will use a medication called MANTADIX 100 mg, which contains amantadine hydrochloride, and compare it to a placebo. The purpose of the study is to see if amantadine can help reduce these motor fluctuations in patients with advanced Parkinson’s disease.

Participants in the study will be randomly assigned to receive either the amantadine capsules or a placebo. The study will last for three months, during which time participants will take the medication daily. Throughout the study, participants will be monitored to see how their motor fluctuations change over time. This will help researchers understand if amantadine is effective in managing these symptoms. The study is designed to be “double-blinded,” meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo, to ensure unbiased results.

By the end of the study, researchers aim to gather information on how well amantadine works in reducing motor fluctuations in people with advanced Parkinson’s disease. This information could be valuable in improving treatment options for those living with this condition. Participants will also be monitored for any side effects to ensure the safety of the medication. The study will provide insights into whether amantadine can be a beneficial add-on therapy for managing symptoms of advanced Parkinson’s disease.